# Inhibition of Anaphylaxis by Ibrutinib

> **NCT03149315** · PHASE2 · COMPLETED · sponsor: **Ann & Robert H Lurie Children's Hospital of Chicago** · enrollment: 6 (actual)

## Conditions studied

- Food Allergy
- Anaphylaxis Food

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03149315
- **Lead sponsor:** Ann & Robert H Lurie Children's Hospital of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-10
- **Primary completion:** 2018-11-14
- **Final completion:** 2018-11-14
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149315, "Inhibition of Anaphylaxis by Ibrutinib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03149315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*